The promoting effect of DNA-PK inhibitors on radiation and topoisomerase II inhibitors has been demonstrated in several hematologic cancers, such as CLL, ALL, CML, AML, APL, and adult T-cell leukemia/lymphoma [181]. The gene discussed is PRKDC; the disease is acute myeloid leukemia.